Trials / Completed
CompletedNCT00371254
A Study of Dasatinib (BMS-354825) in Patients With Advanced 'Triple-negative' Breast Cancer
Phase II Study of Dasatinib (BMS-354825) for Advanced 'Triple-negative' Breast Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 55 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will determine whether the investigational drug dasatinib is effective in treatment of women with progressive advanced triple-negative breast cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dasatinib | Tablets, Oral, 100 mg, twice daily as long as the patient benefits (avg \<6 months) |
| DRUG | Dasatinib | Tablets, Oral, 70 mg, twice daily as long as the patient benefits (avg \<6 months) |
Timeline
- Start date
- 2006-12-01
- Primary completion
- 2008-09-01
- Completion
- 2008-09-01
- First posted
- 2006-09-04
- Last updated
- 2011-03-15
- Results posted
- 2011-03-15
Locations
10 sites across 4 countries: United States, France, Italy, Spain
Source: ClinicalTrials.gov record NCT00371254. Inclusion in this directory is not an endorsement.